CAJ | 학술논문

目的：探究阿托伐他汀对冠心病（CHD）炎症因子hs-CRP、TNF-α和IL-6水平的影响。方法选取2010年1月～2014年7月于南阳市中心医院收治的冠状动脉粥样硬化性心脏病患者160例，采用随机数表法将患者均分为2组（n＝80）。对照组给予活血化瘀、改善微循环等常规治疗，实验组在常规治疗基础上给予阿托伐他汀治疗。观察2组患者治疗前和治疗2个月后炎症因子hs-CRP、TNF-α和IL-6的水平变化，进行比较分析。结果2组患者治疗前hs-CRP、TNF-α和IL-6水平差异均无统计学意义；治疗2个月后2组患者各项指标的差异均有统计学意义（P＜0.05）；实验组患者治疗前后hs-CRP、TNF-α和IL-6水平的差异均有统计学意义（P＜0.05），而对照组患者治疗前后的各项指标的差异均无统计学意义。结论阿托伐他汀可以显著降低冠心病患者血清hs-CRP、TNF-α和IL-6水平，对于冠心病的防治具有重要意义。
목적：탐구아탁벌타정대관심병（CHD）염증인자hs-CRP、TNF-α화IL-6수평적영향。방법선취2010년1월～2014년7월우남양시중심의원수치적관상동맥죽양경화성심장병환자160례，채용수궤수표법장환자균분위2조（n＝80）。대조조급여활혈화어、개선미순배등상규치료，실험조재상규치료기출상급여아탁벌타정치료。관찰2조환자치료전화치료2개월후염증인자hs-CRP、TNF-α화IL-6적수평변화，진행비교분석。결과2조환자치료전hs-CRP、TNF-α화IL-6수평차이균무통계학의의；치료2개월후2조환자각항지표적차이균유통계학의의（P＜0.05）；실험조환자치료전후hs-CRP、TNF-α화IL-6수평적차이균유통계학의의（P＜0.05），이대조조환자치료전후적각항지표적차이균무통계학의의。결론아탁벌타정가이현저강저관심병환자혈청hs-CRP、TNF-α화IL-6수평，대우관심병적방치구유중요의의。
Objective To explore the effects of atorvastatin on inflammatory factors(hs-CRP,TNF-αand IL-6 levels )of coronary heart disease. Methods 160 patients with coronary artery disease were selected which were treated in Nanyang Municipal Central Hospital from January 2010 to July 2014.The 160 CHD patients were divided into two groups using the random number table method.On the basis of conventional treatment,patients of the experimental group were given atorvastatin,but the patients of control group were given only the other conventional treatment.Patients of two groups were tested about inflammatory factors before treatment and after two months treatment,and then analyzed and compared.Results It had no statistically significant difference on hs-CRP,TNF-αand IL-6 levels in patients of the two groups before treatment;it had statistically significant difference on hs-CRP,TNF-αand IL-6 levels in patients of the two groups of two months after treatment(P<0.05 );differences on hs-CRP,TNF-αand IL-6 levels of patients between pre-treatment and after treatment of two months in the experimental group were statistically significant (P<0.05 );however,it was opposite in the control group.Conclusion Atorvastatin could significantly reduce the levels of inflammatory factors(hs-CRP、TNF-αand IL-6)of patients with coronary artery disease.It has important clinical value.